Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children
EAF Simões, L Bont, P Manzoni, B Fauroux… - Infectious diseases and …, 2018 - Springer
Abstract Introduction The REGAL (RSV Evidence–A Geographical Archive of the Literature)
series has provided a comprehensive review of the published evidence in the field of …
series has provided a comprehensive review of the published evidence in the field of …
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
B Resch - Human vaccines & immunotherapeutics, 2017 - Taylor & Francis
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in
children below the age of 5 y. It is associated with up to 63% of all acute respiratory …
children below the age of 5 y. It is associated with up to 63% of all acute respiratory …
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
J Ter Meulen, ABH Bakker, EN Van Den Brink… - The Lancet, 2004 - thelancet.com
SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome
(SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS …
(SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS …
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial
X Carbonell-Estrany, EAF Simões, R Dagan… - …, 2010 - publications.aap.org
OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in
children at high risk by∼ 50% compared with placebo. We compared the efficacy and safety …
children at high risk by∼ 50% compared with placebo. We compared the efficacy and safety …
Safety and immunogenicity of the Ad26. RSV. preF investigational vaccine coadministered with an influenza vaccine in older adults
J Sadoff, E De Paepe, W Haazen… - The Journal of …, 2021 - academic.oup.com
Background Respiratory syncytial virus (RSV) and influenza cause significant disease
burden in older adults. Overlap** RSV and influenza seasonality presents the opportunity …
burden in older adults. Overlap** RSV and influenza seasonality presents the opportunity …
Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children
GJ Robbie, L Zhao, J Mondick… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Although it has been on the market for over a decade, confusion remains regarding the
pharmacokinetics (PK) and optimal dosing of palivizumab, a humanized IgG1κ monoclonal …
pharmacokinetics (PK) and optimal dosing of palivizumab, a humanized IgG1κ monoclonal …
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology
MR Murawski, LW McGinnes, RW Finberg… - Journal of …, 2010 - Am Soc Microbiol
Respiratory syncytial virus (RSV) is the leading cause of serious respiratory infections in
children as well as a serious cause of disease in elderly and immunosuppressed …
children as well as a serious cause of disease in elderly and immunosuppressed …
Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: a real‐world perspective
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of
childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal …
childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal …
Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997–2012
A Doucette, X Jiang, J Fryzek, J Coalson, K McLaurin… - PLoS …, 2016 - journals.plos.org
Background Respiratory syncytial virus (RSV) causes significant pediatric morbidity and is
the most common cause of bronchiolitis. Bronchiolitis hospitalizations declined among US …
the most common cause of bronchiolitis. Bronchiolitis hospitalizations declined among US …
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3 …
Introduction Respiratory syncytial virus (RSV) infection causes respiratory disease
throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a …
throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a …